Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Pengxiang Li, Carmela Benson, Zhi Geng, Sanghyuk Seo, Charmi Patel & Jalpa A. Doshi. (2023) Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. Journal of Medical Economics 26:1, pages 525-536.
Read now
Read now
Anna Kotzeva, Deepali Mittal, Supriya Desai, Davneet Judge & Kunal Samanta. (2023) Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics 26:1, pages 70-83.
Read now
Read now
Dominic Pilon, Charmi Patel, Marie-Hélène Lafeuille, Maryia Zhdanava, Dee Lin, Aurélie Côté-Sergent, Carmine Rossi, Kruti Joshi & Patrick Lefebvre. (2021) Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries. Current Medical Research and Opinion 37:10, pages 1811-1819.
Read now
Read now
Benedicto Crespo-Facorro, Pedro Such, Anna-Greta Nylander, Jessica Madera, Henrike K. Resemann, Emma Worthington, Molly O’Connor, Emma Drane, Sara Steeves & Richard Newton. (2021) The burden of disease in early schizophrenia – a systematic literature review. Current Medical Research and Opinion 37:1, pages 109-121.
Read now
Read now
Wenjie Zhang, Tony B Amos, Stephen W Gutkin, Nicole Lodowski, Emma Giegerich & Kruti Joshi. (2018) A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. ClinicoEconomics and Outcomes Research 10, pages 309-320.
Read now
Read now
Charles Ruetsch, Hyong Un & Heidi C Waters. (2018) Claims-based proxies of patient instability among commercially insured adults with schizophrenia. ClinicoEconomics and Outcomes Research 10, pages 259-267.
Read now
Read now
Dominic Pilon, Matthew Alcusky, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2018) Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. Journal of Medical Economics 21:2, pages 135-143.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, Ignacio Garcia Llinares, Beatriz González Martín Moro, Fadi Tedouri & Kristel Van Impe. (2017) Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. Journal of Medical Economics 20:10, pages 1039-1047.
Read now
Read now
Fan Zhang, Tianmei Si, Chiun-Fang Chiou, Anthony WF Harris, Chang Yoon Kim, Padmashree Jahagirdar & Steve Ascher. (2015) Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 657-668.
Read now
Read now
Jing Wu, Xiaoning He, Li Liu, Wenyu Ye, William Montgomery, Haibo Xue & Jeffery S McCombs. (2015) Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China. Neuropsychiatric Disease and Treatment 11, pages 983-990.
Read now
Read now
Marie-Hélène Lafeuille, Jason Dean, Valerie Carter, Mei Sheng Duh, John Fastenau, Riad Dirani & Patrick Lefebvre. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current Medical Research and Opinion 30:8, pages 1643-1655.
Read now
Read now
Thomas R. Einarson, Roman Zilbershtein, Jana Skoupá, Šárka Veselá, Madhur Garg & Michiel E. H. Hemels. (2013) Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. Journal of Medical Economics 16:9, pages 1089-1095.
Read now
Read now
Angelika Mehnert, Deborah Nicholl, Hanna Pudas, Monique Martin & Alistair McGuire. (2012) Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of Medical Economics 15:5, pages 844-861.
Read now
Read now
Natalie C. Edwards, Erik Muser, Dilesh Doshi & John Fastenau. (2012) The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. Journal of Medical Economics 15:4, pages 623-634.
Read now
Read now
Articles from other publishers (50)
Anirban BasuCarmela BensonIbrahim TurkozCharmi PatelPamela BakerBrianne Brown. (2022) Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Journal of Managed Care & Specialty Pharmacy 28:10, pages 1086-1095.
Crossref
Crossref
Alexander Diamond, Steven M. Silverstein & Brian P. Keane. (2022) Visual system assessment for predicting a transition to psychosis. Translational Psychiatry 12:1.
Crossref
Crossref
Jacqueline PesaDavid RotterEros PapademetriouRavi PotluriCharmi PatelCarmela Benson. (2022) Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database. Journal of Managed Care & Specialty Pharmacy 28:1, pages 26-38.
Crossref
Crossref
Rwnk Kadhim Jwad, Dheyaa Jabbar Kadhim, Mohammed Hadi Munshed Alosami & Laith G. Shareef. (2022) Medication-related burden among Iraqi patients with rheumatoid arthritis: An observational study. F1000Research 11, pages 1047.
Crossref
Crossref
Hawraa Kadhim Abbas, Dheyaa Jabbar Kadhim, Faiq Isho Gorial & Laith G. Shareef. (2022) Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research 11, pages 970.
Crossref
Crossref
Hawraa Kadhim Abbas, Dheyaa Jabbar Kadhim, Faiq Isho Gorial & Laith G. Shareef. (2022) Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research 11, pages 970.
Crossref
Crossref
Pedro Bonifácio Fernandes Júnior, Adriely Portela Souza Lima, Caio Flávio Nascimento Mendes Ouriques, Caroline Duarte de Almeida, Cibelle da Silva Torres, Fernando de Lima Minari, Juliana Marino Maia, Larissa Rodrigues Cardoso Santos, Lorena Ponzetto Rosilho de Liz, Lucas Pinheiro Brito, Priscilla Nery Tavares Pereira, Igor de Sousa Oliveira, Yana Sarah Fernandes Souza Ribeiro & Gilberto Loiola de Vasconcelos. (2021) Manejo do paciente em primeiro episódio de surto psicótico. Revista Científica Multidisciplinar Núcleo do Conhecimento, pages 22-42.
Crossref
Crossref
Timothy J. Onofrychuk, Shuang Cai, Dan L. McElroy, Andrew J. Roebuck, Quentin Greba, Sumanta Garai, Ganesh A. Thakur, Robert B. Laprairie & John G. Howland. (2021) Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Progress in Neuro-Psychopharmacology and Biological Psychiatry 109, pages 110235.
Crossref
Crossref
Dan L. McElroy, Andrew J. Roebuck, Gavin A. Scott, Quentin Greba, Sumanta Garai, Eileen M. Denovan-Wright, Ganesh A. Thakur, Robert B. Laprairie & John G. Howland. (2021) Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology 238:4, pages 1087-1098.
Crossref
Crossref
Claudia Carmassi, Francesca Milani, Carlo Antonio Bertelloni, Enrico Massimetti, Angelo Cerù & Liliana Dell’Osso. (2020) Comparing re‐hospitalisation rates in a real‐world naturalistic 24‐month follow‐up of psychotic patients with different treatment strategies: Oral versus LAI antipsychotics. International Journal of Clinical Practice 75:3.
Crossref
Crossref
Jason M Noel & Cherry W Jackson. (2020) ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. American Journal of Health-System Pharmacy 77:24, pages 2114-2132.
Crossref
Crossref
Yuan Feng, Jianguo Shi, Lili Wang, Xia Zhang, Yunlong Tan, Jingyuan Zhao, Yuping Ning, Shiping Xie, Xuejun Liu, Qi Liu, Keqing Li, Xiaoliang Wang, Lehua Li, Xiufeng Xu, Wei Deng, Xiaoyan Luo & Gang Wang. (2020) Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry and Clinical Neurosciences 74:6, pages 336-343.
Crossref
Crossref
Anna Wallace, Keith Isenberg, Whitney York, Mayura Shinde, John Barron, Jessica Franchino-Elder, Michael Sand & Matthew Sidovar. (2020) Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection. Schizophrenia Research 215, pages 392-398.
Crossref
Crossref
Kuang Ming Kuo, Paul C. Talley, Chi Hsien Huang & Liang Chih Cheng. (2019) Predicting hospital-acquired pneumonia among schizophrenic patients: a machine learning approach. BMC Medical Informatics and Decision Making 19:1.
Crossref
Crossref
Anna WallaceJohn BarronWhitney YorkKeith IsenbergJessica Franchino-ElderMatthew SidovarMichael Sand. (2019) Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1102-1110.
Crossref
Crossref
Sam Reid & Sagnik Bhattacharyya. (2019) Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. Psychiatry Research 280, pages 112523.
Crossref
Crossref
Nora Palomar-Ciria, Fanny Cegla-Schvartzman, Javier-David Lopez-Morinigo, Hugo J. Bello, Santiago Ovejero & Enrique Baca-García. (2019) Diagnostic stability of schizophrenia: A systematic review. Psychiatry Research 279, pages 306-314.
Crossref
Crossref
Anna WallaceJohn BarronWhitney YorkKeith IsenbergJessica Franchino-ElderMatthew SidovarMichael Sand. (2019) Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis. Journal of Managed Care & Specialty Pharmacy, pages 1-10.
Crossref
Crossref
Meghamala S. Tavaragi & Sushma C.. 2019. Chronic Illness and Long-Term Care. Chronic Illness and Long-Term Care
445
467
.
Jae Hoon JeongMin Jeong KangMin Young KwonSang Min LeeKyu Young Lee. (2019) The Effectiveness on Prevention of Rehospitalization with Long-Term Psychosocial Interventions for Patients with Major Psychiatric Disorders. Korean Journal of Schizophrenia Research 22:2, pages 66.
Crossref
Crossref
Peng Men, Zhanmiao Yi, Chaoyun Li, Shuli Qu, Tengbin Xiong, Xin Yu & Suodi Zhai. (2018) Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC Psychiatry 18:1.
Crossref
Crossref
Andrew J. Roebuck, Wendie N. Marks, Max C. Liu, Nimra B. Tahir, Nadine K. Zabder, Terrance P. Snutch & John G. Howland. (2018) Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801. Psychopharmacology 235:11, pages 3339-3350.
Crossref
Crossref
Mariana C. Diana, Fernanda F. Peres, Veronica Justi, Rodrigo A. Bressan, Acioly L. T. Lacerda, José Alexandre Crippa, Jaime E. C. Hallak & Vanesssa Costhek Abilio. (2018) Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain. CNS Neuroscience & Therapeutics 24:7, pages 624-632.
Crossref
Crossref
Kimberlee J. Trudeau, Joanna Burtner, Albert J. Villapiano, Megan Jones, Stephen F. Butler & Kruti Joshi. (2018) Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation. Journal of Nervous & Mental Disease 206:7, pages 528-536.
Crossref
Crossref
Michael Schoenbaum, Jason M Sutherland, Andre Chappel, Susan Azrin, Amy B Goldstein, Agnes Rupp & Robert K Heinssen. (2017) Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States. Schizophrenia Bulletin 43:6, pages 1262-1272.
Crossref
Crossref
Mark Pennington & Paul McCrone. (2017) The Cost of Relapse in Schizophrenia. PharmacoEconomics 35:9, pages 921-936.
Crossref
Crossref
Hsin-Hui Huang, Chuan-Yu Chen, Jen-Huoy Tsay, Yiing-Jenq Chou & Nicole Huang. (2017) Factors in Maintaining a Stable Patient–Physician Relationship among Individuals with Schizophrenia. Community Mental Health Journal 53:5, pages 578-588.
Crossref
Crossref
Natisha Sands, Stephen Elsom, Rebecca Corbett, Sandra Keppich-Arnold, Roshani Prematunga, Michael Berk & Julie Considine. (2017) Predictors for clinical deterioration of mental state in patients assessed by telephone-based mental health triage. International Journal of Mental Health Nursing 26:3, pages 226-237.
Crossref
Crossref
Meghamala S. Tavaragi & Sushma C.. 2017. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment
164
186
.
Laith AL-EITAN, Sahar AL-HABAHBEH & Rami ALKHATIB. (2017) Genetic association analysis of ERBB4 polymorphisms with the risk ofschizophrenia susceptibility in a Jordanian population of Arab descent. TURKISH JOURNAL OF MEDICAL SCIENCES 47, pages 542-553.
Crossref
Crossref
Lan Gao, Hao Hu, Fei-Li Zhao & Shu-Chuen Li. (2016) Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLOS ONE 11:1, pages e0147169.
Crossref
Crossref
Basant Pradhan & Narsimha R. Pinninti. 2016. Brief Interventions for Psychosis. Brief Interventions for Psychosis
55
87
.
Huali Lin, Ying Lei, Bo Zhang, Zunxiao Dai & Xiaoyun Lu. (2015)
Common variants of
HTR1A
and
SLC6A4
confer the increasing risk of Schizophrenia susceptibility: A population-based association and epistasis analysis
. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 168:8, pages 749-755.
Crossref
Crossref
Mariana C. Diana, Marcos L. Santoro, Gabriela Xavier, Camila Mauricio Santos, Leticia N. Spindola, Patrícia N. Moretti, Vanessa K. Ota, Rodrigo A. Bressan, Vanessa C. Abilio & Sintia I. Belangero. (2015) Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR). Psychiatry Research 229:3, pages 690-694.
Crossref
Crossref
Lars Helldin, Joseph Peuskens, Roland Vauth, Emilio Sacchetti, Haye bij de Weg, Hasan Herken, Marjolein Lahaye & Andreas Schreiner. (2015) Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia. Therapeutic Advances in Psychopharmacology 5:4, pages 194-207.
Crossref
Crossref
Adem Sav, Michelle A. King, Jennifer A. Whitty, Elizabeth Kendall, Sara S. McMillan, Fiona Kelly, Beth Hunter & Amanda J. Wheeler. (2015) Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expectations 18:3, pages 312-324.
Crossref
Crossref
Erica A. Voss, Patrick B. Ryan, Paul E. Stang, David Hough & Larry Alphs. (2015) Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics. International Clinical Psychopharmacology 30:3, pages 151-157.
Crossref
Crossref
Marie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Fortier, Erik Muser, John Fasteneau, Mei Sheng Duh & Patrick Lefebvre. (2015) Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. American Journal of Health-System Pharmacy 72:5, pages 378-389.
Crossref
Crossref
Mara De Maio, Patricia Graham, David Vaughan, Lawrence Haber & Steven Madonick. (2015) Review of international early psychosis programmes and a model to overcome unique challenges to the treatment of early psychosis in the United States. Early Intervention in Psychiatry 9:1, pages 1-11.
Crossref
Crossref
Chiachen Cheng, Carolyn S. Dewa, Gord Langill, Mirella Fata & Desmond Loong. (2014) Rural and remote early psychosis intervention services: the Gordian knot of early intervention. Early Intervention in Psychiatry 8:4, pages 396-405.
Crossref
Crossref
Kaisa Kauppi, Maritta Välimäki, Heli M Hätönen, Lauri M Kuosmanen, Katja Warwick-Smith & Clive E Adams. (2014) Information and communication technology based prompting for treatment compliance for people with serious mental illness. Cochrane Database of Systematic Reviews 2014:6.
Crossref
Crossref
Ye. G. Kornetova & A. V. Semke. (2014) CONTEMPORARY ISSUES AND PERSPECTIVES ON THE STUDYING OF SCHIZOPHRENIA WITH NEGATIVE SYMPTOMS LEADING. Bulletin of Siberian Medicine 13:1, pages 5-13.
Crossref
Crossref
Marie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, Christian Frois, John Fastenau & Mei Sheng Duh. (2013) Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13:1.
Crossref
Crossref
Lin Xie, M. Furaha Kariburyo, Juan Du & Yuexi Wang. (2013) Assessing the Economic Burden and Health Care Utilizations of U.S. Veteran Patients with Schizophrenia. Journal of Health Economics and Outcomes Research 1:2, pages 174-183.
Crossref
Crossref
Thomas R. Einarson, Colin Vicente, Roman Zilbershtein, Charles Piwko, Christel N. Bø, Hanna Pudas & Michiel E. H. Hemels. (2013) Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatrica 25:2, pages 85-94.
Crossref
Crossref
Marco DiBonaventura, Susan Gabriel, Leon Dupclay, Shaloo Gupta & Edward Kim. (2012) A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12:1.
Crossref
Crossref
Yelena GullerGiulio TononiBradley R. Postle. (2012) Conserved Functional Connectivity but Impaired Effective Connectivity of Thalamocortical Circuitry in Schizophrenia. Brain Connectivity 2:6, pages 311-319.
Crossref
Crossref
Maritta Välimäki, Kaisa Kauppi, Heli Hätönen, Lauri Kuosmanen, Katja Warwick-Smith & Clive E Adams. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ahmed D. Mohamed & Barbara J. Sahakian. (2011) The ethics of elective psychopharmacology. The International Journal of Neuropsychopharmacology 15:04, pages 559-571.
Crossref
Crossref
Nicolas M Furiak, James C Gahn, Robert W Klein, Stephen B Camper & Kent H Summers. (2012) Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Annals of General Psychiatry 11:1, pages 29.
Crossref
Crossref